Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR)

Condition

Non-alcoholic Steatohepatitis (NASH)

Interventions

Drug:Placebo

Drug:Tropifexor (LJN452)

ClinicalTrials.gov identifier

NCT02855164

Novartis reference number

CLJN452A2202

Phase

Phase 2

This study is Terminated.

Official title

A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR

Purpose

The purpose of the study was to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH